Controverses sur le dépistage et la prise en charge des dyslipidémies familiales en 2020 [Controversies concerning screening and treatment of primary dyslipidemias in 2020]

Détails

ID Serval
serval:BIB_24A64741D9AA
Type
Article: article d'un périodique ou d'un magazine.
Collection
Publications
Institution
Titre
Controverses sur le dépistage et la prise en charge des dyslipidémies familiales en 2020 [Controversies concerning screening and treatment of primary dyslipidemias in 2020]
Périodique
Revue medicale suisse
Auteur(s)
Bretagne L., Aubert C., Nanchen D., Rodondi N.
ISSN
1660-9379 (Print)
ISSN-L
1660-9379
Statut éditorial
Publié
Date de publication
04/03/2020
Peer-reviewed
Oui
Volume
16
Numéro
684
Pages
433-437
Langue
français
Notes
Publication types: Journal Article ; Review
Publication Status: ppublish
Résumé
Familial dyslipidemia is rare compared to polygenetic causes. Nevertheless, it is important not to miss this diagnosis, as it is more strongly associated with an increased risk of early cardiovascular disease and scores for calculating cardiovascular risk are not valid in this population. Early detection and management based on lifestyle optimization and treatment of cardiovascular risk factors can delay the onset of cardiovascular complications and thus improve patients' quality of life. A LDL-Cholesterol of 4,9 mmol/l has recently been suggested as the cut-off for starting lipid lowering therapy, but remains controversial because the majority of people above this threshold do not have primary monogenic dyslipidemia. The age at which therapy should be initiated as well as the targets for treatment are also controversial.
Mots-clé
Cholesterol, LDL/blood, Dyslipidemias/blood, Dyslipidemias/diagnosis, Dyslipidemias/genetics, Dyslipidemias/therapy, Humans, Hydroxymethylglutaryl-CoA Reductase Inhibitors/therapeutic use, Quality of Life, Risk Factors
Pubmed
Création de la notice
19/03/2020 17:29
Dernière modification de la notice
03/02/2021 7:26
Données d'usage